ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study

December 31, 2010

Other DCT Concepts Approved By BSC

June 6, 1986

Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program

August 27, 1982

Shubik applauded for NCAB Service

February 12, 1982

NCI Lists Projected Grant Paylines

February 16, 1996

NCI Increases R01 Grant Payline From 12th to 15th Percentile.

June 29, 2007